Utilization, Utility, and Variability in Usage of Adjunctive Hyperbaric Oxygen Therapy in Spinal Management: A Review of the Literature

Kurt D Knepley, Jennifer Z Mao, Patrick S Laird, Nicholas S Imperato, Asham Khan, Justice O Agyei, Tim E O'Connor, John Pollina, Jeffrey P Mullin

The objective of this review was to understand the clinical utilization, utility, and variability in the usage of adjunctive hyperbaric oxygen therapy (HBOT). Surgical site infection is associated with high morbidity and mortality, increased health care expenditure, and decreased quality of life. With the increasing prevalence of adult spinal deformity and spinal fusion surgery, it is imperative to understand the potential benefits of adjunctive treatments. HBOT is a safe and common procedure indicated to treat various medical conditions. We conducted a literature search across 3 databases for English articles published between December 1, 2019 and December 1, 2000. Thirteen studies were included. HBOT may lessen the duration of antimicrobial therapy and mitigate instrument removal and revision surgery. The current usage indications for HBOT are supported by level III evidence for chronic osteomvelitis and level IV evidence for osteoradionecrosis. However, the same level of evidence exists to support the beneficial use of adjunctive HBOT for noncomplicated spinal infections within 2 months after surgery. When cultured, the most common organisms were Staphylococcus aureus and other low-virulence organisms. The most common treatment protocol consists of 90-minute sessions of 100% Fio_2 at 2-3 atmosphere absolute with a mean of 35.3 ± 11.6 sessions for 5.2 ± 1.4 weeks. Adjunctive HBOT should be considered in select high-risk patients. Further improvements in diagnosis and categorization of spinal infections are necessary and will indelibly aid the decision making for the initiation of HBOT.

PCOM®

Inanmaz et al. ²⁴ 201 Körpınar et al. ⁶ 201 Ahmed et al. ²⁵ 200 Eltorai et al. ²⁶ 198 Kutlay et al. ² 200	14 III 19 III 09 IV 34 III	42 19 6	NA 10	16	39 (18—66)	In prevention of postoperative deep infection in	17% infection rate with hyperbaric
Körpınar et al. ⁶ 201 Ahmed et al. ²⁵ 200 Eltorai et al. ²⁶ 198 Kutlay et al. ⁷ 200	19 III 09 IV 34 III	19 6	10	67		patients with neuromuscular scollosis	oxygen therapy
Ahmed et al. ²⁵ 200 Eltorai et al. ²⁶ 198 Kutlay et al. ⁷ 200	09 IV 34 III	6		57	11 (1-36)	In the treatment of pyogenic spinal infections	92% recovery rate
Eltorai et al. ²⁶ 198 Kutlay et al. ⁷ 200	34 III		3	53	23 (5-60)	In the treatment of spinal osteomyelitis	83% recovery rate (without relapse)
Kutlay et al. ⁷ 200		44	0	(24—83)	(6—108)	In patients with spinal cord injury with chronic osteomyelitis	68% recovery rate
	III 80	22	8	45	24	In postoperative discitis	100% recovery rate‡
Onen et al.27 201	15 IV	19	9	55	23 (10-50)	In refractory iatrogenic spinal infections	100% recovery rate (without revision)
Tofuku et al. ¹² 201	14	23	10	69	28 (12-48)	Adjunctive to percutaneous drainage in pyogenic spondylitis with iliopsoas abscess	100% recovery rate
Kohshi et al. ²⁸ 200	05 IV	1	0	49	6	In cervical epidural abscess	100% recovery rate
Topuz et al. ²⁹ 200	09	35	16	(25—29)	60	In spinal tuberculosis with antituberculosis agents and surgical debridement	100% recovery rate‡
Larsson et al. ^{13,} § 200)2 III	7	23	45	30 (17-46)	In neurosurgical infections after craniotomies or laminectomies	60% noninstrumentation removal
Larsson et al. ³⁰ 201	11 IV	6	NA	11	54 (37—72)	In pediatric patients with neuromuscular spine deformities for deep postoperative infections	100% recovery rate
West et al. ³¹ 201	19 IV	2	0	53	18	In the setting of craniocervical posterior fusion	80% outcome improvement
Donovan et al. ³² 200	05 IV	3	0	67	48	In the setting of cervical osteoradionecrosis undergoing vascularized fibular graft and craniocervical posterior fusion	100% recovery rate